122 related articles for article (PubMed ID: 21983344)
1. Imperatorin prevents cardiac hypertrophy and the transition to heart failure via NO-dependent mechanisms in mice.
Zhang Y; Cao Y; Duan H; Wang H; He L
Fitoterapia; 2012 Jan; 83(1):60-6. PubMed ID: 21983344
[TBL] [Abstract][Full Text] [Related]
2. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
3. Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Asanuma H; Minamino T; Tomoike H; Hori M; Kitakaze M
Cardiovasc Res; 2005 Mar; 65(4):879-88. PubMed ID: 15721868
[TBL] [Abstract][Full Text] [Related]
4. Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo.
Zhang Y; Cao Y; Zhan Y; Duan H; He L
Fitoterapia; 2010 Dec; 81(8):1188-95. PubMed ID: 20691250
[TBL] [Abstract][Full Text] [Related]
5. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model.
Liao Y; Takashima S; Asano Y; Asakura M; Ogai A; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Ogita H; Tomoike H; Hori M; Kitakaze M
Circ Res; 2003 Oct; 93(8):759-66. PubMed ID: 12970111
[TBL] [Abstract][Full Text] [Related]
6. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats.
Zhang CX; Pan SN; Meng RS; Peng CQ; Xiong ZJ; Chen BL; Chen GQ; Yao FJ; Chen YL; Ma YD; Dong YG
Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):55-62. PubMed ID: 21083698
[TBL] [Abstract][Full Text] [Related]
7. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure.
Ohtani T; Mano T; Hikoso S; Sakata Y; Nishio M; Takeda Y; Otsu K; Miwa T; Masuyama T; Hori M; Yamamoto K
J Hypertens; 2009 May; 27(5):1074-83. PubMed ID: 19349910
[TBL] [Abstract][Full Text] [Related]
8. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
Gao S; Long CL; Wang RH; Wang H
Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied Mice.
Han F; Lu YM; Hasegawa H; Kanai H; Hachimura E; Shirasaki Y; Fukunaga K
J Pharmacol Exp Ther; 2010 Feb; 332(2):421-8. PubMed ID: 19889795
[TBL] [Abstract][Full Text] [Related]
10. L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways.
Lin Y; Wang LN; Xi YH; Li HZ; Xiao FG; Zhao YJ; Tian Y; Yang BF; Xu CQ
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):124-30. PubMed ID: 18816294
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
Tokudome T; Horio T; Kishimoto I; Soeki T; Mori K; Kawano Y; Kohno M; Garbers DL; Nakao K; Kangawa K
Circulation; 2005 Jun; 111(23):3095-104. PubMed ID: 15939815
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro.
Wen Y; Zhang XJ; Ma YX; Xu XJ; Hong LF; Lu ZH
Scand J Clin Lab Invest; 2009; 69(4):518-25. PubMed ID: 19347742
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure.
Li XM; Ma YT; Yang YN; Liu F; Chen BD; Han W; Zhang JF; Gao XM
Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1054-61. PubMed ID: 19566828
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Liao Y; Zhao H; Ogai A; Kato H; Asakura M; Kim J; Asanuma H; Minamino T; Takashima S; Kitakaze M
Hypertens Res; 2008 Feb; 31(2):335-44. PubMed ID: 18360054
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.
Calderone A; Thaik CM; Takahashi N; Chang DL; Colucci WS
J Clin Invest; 1998 Feb; 101(4):812-8. PubMed ID: 9466976
[TBL] [Abstract][Full Text] [Related]
16. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.
Zhang P; Xu X; Hu X; van Deel ED; Zhu G; Chen Y
Circ Res; 2007 Apr; 100(7):1089-98. PubMed ID: 17363700
[TBL] [Abstract][Full Text] [Related]
17. Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis.
Kazakov A; Müller P; Jagoda P; Semenov A; Böhm M; Laufs U
Cardiovasc Res; 2012 Mar; 93(3):397-405. PubMed ID: 22106415
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy alters nitric oxide synthase and natriuretic peptide systems in the rat left ventricle.
Jankowski M; Wang D; Mukaddam-Daher S; Gutkowska J
J Endocrinol; 2005 Jan; 184(1):209-17. PubMed ID: 15642797
[TBL] [Abstract][Full Text] [Related]
19. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart.
Tokudome T; Kishimoto I; Horio T; Arai Y; Schwenke DO; Hino J; Okano I; Kawano Y; Kohno M; Miyazato M; Nakao K; Kangawa K
Circulation; 2008 May; 117(18):2329-39. PubMed ID: 18443239
[TBL] [Abstract][Full Text] [Related]
20. eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression.
Flaherty MP; Brown M; Grupp IL; Schultz JE; Murphree SS; Jones WK
Cardiovasc Toxicol; 2007; 7(3):165-77. PubMed ID: 17901560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
